FDA approves blood disorder drug made by Japan's Shionogi

(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd’s treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

The treatment belongs to a new class of drugs called thrombopoietin receptor agonists (TPO RA), which stimulate platelet production.

Its approval is the second for this class of drug for liver disease patients, following the FDA’s greenlight for U.S.-based Dova Pharmaceuticals’ rival treatment in May.

Reporting by Manas Mishra in Bengaluru


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more